Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue

Histopathology

Volumn 53, Issue 2, 2008, Pages 177-183

  Brimo, F ^b   Vollmer, R T ^c   Corcos, J ^d   Kotar, K ^e   Begin L R ^f   Humphrey, P A ^g   Bismar, T A ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^g BARNES JEWISH HOSPITAL   (United States)

Author keywords

Cancer length; Discontinuous; Millimetric; Needle biopsy; Prostatic cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORPHOMETRICS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 47749145771     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03087.x     Document Type: Article

References (30)

1. Briganti A, Chun FK, Salonia A et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur. Urol. 2006 49 1019 1026 discussion 1026-1027.
2. Chun FK, Steuber T, Erbersdobler A et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur. Urol. 2006 49 820 826.
3. D'Amico AV, Whittington R, Malkowicz SB et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 1999 17 168 172.
4. D'Amico AV, Whittington R, Malkowicz SB et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J. Clin. Oncol. 2000 18 1164 1172.
5. Graefen M, Noldus J, Pichlmeier U et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumour characteristics. Eur. Urol. 1999 36 21 30.
6. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 1998 90 766 771.
7. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 1997 79 528 537.
8. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 1445 1451.
9. Sebo TJ, Cheville JC, Riehle DL et al. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001 91 2196 2204.
10. Lewis JS Jr., Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumour volume in a screening population. Am. J. Clin. Pathol. 2002 118 442 450.
11. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J. Urol. 1993 150 1845 1850.
12. Badalament RA, Miller MC, Peller PA et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J. Urol. 1996 156 1375 1380.
13. Bostwick DG, Qian J, Bergstralh E et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J. Urol. 1996 155 1361 1367.
14. Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J. Urol. 1998 159 2023 2029.
15. D'Amico AV, Whittington R, Malkowicz SB et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997 49 (3A Suppl. 23 30.
16. Egan AJ, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis. Am. J. Surg. Pathol. 1997 21 1496 1500.
17. Epstein JI, Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J. Urol. 2001 166 402 410.
18. Gardner TA, Lemer ML, Schlegel PN, Waldbaum RS, Vaughan ED Jr., Steckel J. Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume. Br. J. Urol. 1998 81 839 843.
19. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol. 1996 156 1059 1063.
20. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J. Urol. 2002 167 2032 2035 discussion 2036.
21. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994 44 371 376.
22. Rubin MA, Bassily N, Sanda M, Montie J, Strawderman MS, Wojno K. Relationship and significance of greatest percentage of tumour and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am. J. Surg. Pathol. 2000 24 183 189.
23. Tigrani VS, Bhargava V, Shinohara K, Presti JC Jr. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy. Urology 1999 54 689 693.
24. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998 51 759 764.
25. Bismar TA, Lewis JS Jr., Vollmer RT, Humphrey PA. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am. J. Surg. Pathol. 2003 27 432 440.
26. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv. Anat. Pathol. 2006 13 57 59.
27. AJCC. AJCC Cancer Staging Manual, 6th edn. Berlin: Springer, 2002.
28. Briganti A, Chun FK, Hutterer GC et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. Eur. Urol. 2007 52 733 743.
29. Rubin MA, Bismar TA, Curtis S, Montie JE. Prostate needle biopsy reporting: how are the surgical members of the Society of Urologic Oncology using pathology reports to guide treatment of prostate cancer patients? Am. J. Surg. Pathol. 2004 28 946 952.
30. Rubin MA, Mucci NR, Manley S et al. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumour be predicted preoperatively? J. Urol. 2001 165 114 118.